Zaynich (cefepime-zidebactam) is a novel antibacterial therapy for complicated urinary tract infections (cUTI) and serious infections caused by multidrug-resistant Gram-negative bacteria. The cefepime/zidebactam combination is designed to overcome resistance mechanisms and restore antibiotic activity against difficult-to-treat pathogens.
Antimicrobial resistance remains a challenge to healthcare systems globally, and Zaynich offers an important new option for the treatment of bacterial infections that are resistant to drugs. The novel mechanism of action results in improved clinical outcomes and supports global initiatives to fight antibiotic resistance and preserve the effectiveness of modern antimicrobial treatments.
